Nizatidine Recall Issued As FDA Finds NDMA Contamination In Another Heartburn Drug
A second generic Axid recall has been issued due to high levels of NDMA, a known carcinogen.
A second generic Axid recall has been issued due to high levels of NDMA, a known carcinogen.
A generic Axid recall has been issued after the discovery of trace amounts of NDMA in the active ingredient.
FDA testing does not find that Zantac turns into NDMA in the stomach, but does confirm high enough levels of the carcinogen to justify Zantac recalls.